588702-68-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-(trifluoromethyl)isonicotinate is utilized as a key intermediate in the synthesis of various pharmaceutical drugs, specifically those with anti-inflammatory and anti-anxiety effects. Its presence in these medications contributes to their therapeutic properties, making it an essential component in the development of such treatments.
Used in Organic Chemistry Research:
In the field of organic chemistry, methyl 2-(trifluoromethyl)isonicotinate is employed as a building block for constructing intricate chemical structures. Its unique properties allow for the creation of complex molecules that can be used in further research and development, expanding the possibilities for new chemical compounds and their applications.
Used in Biochemistry and Pharmacology Research:
Methyl 2-(trifluoromethyl)isonicotinate also finds application in biochemistry and pharmacology research, where it is used to study the interactions of various compounds with biological systems. This research can lead to a better understanding of how these compounds can be used in the development of new drugs and therapies, ultimately benefiting the field of medicine.

InChI:InChI=1S/C8H6F3NO2/c1-14-7(13)5-2-3-12-6(4-5)8(9,10)11/h2-4H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 124-38-9 carbon dioxide 
• 368-48-9 2-(trifluoromethyl)pyridine 
• 58481-10-0 2-iodopyridine-4-carboxylic acid 
• 134579-47-8 methyl 2-iodoisonicotinate 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 887583-90-6 4-bromo-2-(trifluoromethyl)pyridine 
• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 131748-14-6 4-chloro-2-trifluoromethylpyridine 
• 916210-02-1 2-(trifluoromethyl)pyridine-4-carbonitrile 
• 590371-73-6 2-(trifluoromethyl)pyridine-4-iodide 
• 1263378-63-7 4-bromo-2-trifluoromethylpyridine hydrobromide 

Downstream Products

• 916304-20-6 2-trifluoromethyl-4-(aminomethyl)pyridine 

Relevant academic research and scientific papers

QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS

The disclosure includes compounds of Formula (I) and Formula(A) wherein R1, R2, R3, m, n, k, and L are defined herein. Also disclosed are methods for treating a neoplastic disease, autoimmune disease, or an inflammatory disorder with these compounds.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF

The present disclosure provides a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds. They are kinase inhibitors potentially useful in the tre

Efficient copper-catalyzed trifluoromethylation of aromatic and heteroaromatic iodides: The beneficial anchoring effect of borates

Efficient copper-catalyzed trifluoromethylation of aromatic iodides was achieved with TMSCF3 in the presence of trimethylborate. The Lewis acid was used to anchor the in situ generated trifluoromethyl anion and suppress its rapid decomposition. Broad applicability of the new trifluoromethylating reaction was demonstrated in the functionalization of different aromatic and heteroaromatic iodides.

PROCESS FOR THE PREPARATION OF 2-TRIFLUOROMETHYL ISONICOTINIC ACID AND ESTERS

The invention relates to a novel process for the preparation of 2- trifluoromethyl isonicotinic acid and esters of the formula I which involves a palladium catalysed carbonylation or cyanation step wherein R1 is hydrogen or Q1-6-alkyl. The 2-trifluoromethyl isonicotinic acid and esters of the formula I are versatile intermediates for the preparation of active pharmaceutical and agrochemical agents such as for instance TAAR 1 agonists of the formula III.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

The direct metalation and subsequent functionalization of trifluoromethyl-substituted pyridines and quinolines

Depending on the choice of the reagent, 2-(trifluoromethyl)-pyridine can be selectively metalated and subsequently carboxylated of otherwise functionalized either at the 3- or at the 6-position. "Optional site selectivity" can also be achieved with 4-(trifluoromethyl)pyridine, which may be deprotonated either at the 2- or at the 3-position. In contrast, 3-(trifluoromethyl)pyridine undergoes nucleophilic addition and ensuing decomposition whatever the base. Depending on the reaction conditions, 2-(trifluoromethyl)quinoline displays reactivity toward lithium reagents at its 3-, 4-, or 8-positions, 3-(trifluoromethyl)quinolines at the 2- or 4-positions, and 4-(trifluoromethyl)quinoline at the 2- or 3-positions. It was therefore possible to prepare four trifluoromethyl-substituted pyridinecarboxylic acids (1, 4, 9, and 10) and six trifluoromethyl-substituted quinolinecarboxylic acids (11, 13, 14, 15, 17, and 18) regioisomerically uncontaminated and in a most straightforward way. ( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003).